drugset / Trial / NCT00261079
Fexofenadine in Pruritic Skin Disease
RandomizedParallel-groupOpen-labelTreatment
Summary
Primary objective: * To compare the efficacy and safety profile of Fexofenadine 180mg tablets plus prednicarbate(2.5mg/g) vs prednicarbate(2.5mg/g) alone in the treatment of pruritic skin disease Secondary objective: * To evaluate patient's satisfaction of Allegra treatment
Timeline
- Start
- 2005-04
- Primary completion
- —
- Completion
- 2006-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Fexofenadine | Unknown | 180 mg | — |
Indications
No indication recorded.